Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial

JAMA

Volumn 280, Issue 17, 1998, Pages 1490-1496

  Testa, Marcia A ^a   Simonson, Donald C ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; EMPLOYMENT; FEMALE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT;

EID: 0032483719     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.17.1490     Document Type: Article

References (28)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. United Kingdom Prospective Diabetes Study (UKPDS) Group. UKPDS 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed noninsulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
3. Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious cycle. Diabetes. 1992;41:255-260.
4. Cryer PE, Binder C, Bolli GB, et al. Hypoglycemia in IDDM. Diabetes. 1989;38:1193-1199.
5. Gonder-Frederick LA, Cox DJ. Symptom and blood glucose feedback in the self-treatment of IDDM. In: Holmes CS, ed. Neuropsychological and Behavioral Aspects of Diabetes. New York, NY: Springer-Verlag; 1990:155-174.
6. Draelos MT, Jacobson AM, Weinger MA, et al. Cognitive function in patients with insulin-dependent diabetes mellitus during hyperglycemia and hypoglycemia. Am J Med. 1995;98:135-144.
7. Weinger K, Jacobson AM, Draelos MT, et al. Blood glucose estimation and symptoms during hyperglycemia and hypoglycemia in patients with insulin-dependent diabetes mellitus. Am J Med. 1995; 98:22-31.
8. Weinberger M, Kirkman M, Samsa GP, et al. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Med Care. 1994;29: 1173-1181.
9. Bagne CA, Luscombe FA, Damiano A. Relationships between glycemic control, diabetes-related symptoms and SF-36 scales scores in patients with non-insulin dependent diabetes mellitus. Qual Life Res. 1995;4:392-393.
10. Hanestad BR, Graue M. To maintain quality of life and satisfactory metabolic control in Type II diabetes patients. Qual Life Res. 1995;4:436-437.
11. Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trials. Diabetes Care. 1996;19:195-203.
12. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA. 1996;276:1409-1415.
13. Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992;3(suppl 4):S111-S119.
14. Harris MI, Eastman RC, Siebert C. The DCCT and medical care for diabetes in the US. Diabetes Care. 1994;17:761-764.
15. DCCT Study Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1468-1478.
16. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. Diabetes Care. 1997;20:735-744.
17. Van der Does FEE, De Neeling JND, Snoek FJ, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care. 1996; 19:204-210.
18. Testa MA, Simonson DC. Measuring quality of life in hypertensive patients with diabetes. Postgrad Med J. 1988;64(suppl 3):50-58.
19. Testa MA, Hollenberg NK, Anderson RA, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine GITS. Am J Hypertens. 1991;4: 363-373.
20. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. N Engl J Med. 1993;328:907-913.
21. Testa MA, Simonson DC. Assessing quality-of-life outcomes. N Engl J Med. 1996;334:835-840.
22. Testa MA, Nackley J. Methods for quality of life studies. Annu Rev Public Health. 1994;15:535-559.
23. US Bureau of the Census. Statistical Abstract of the United States: 1995. 115th ed. Washington, DC: US Bureau of the Census; 1995.
24. American Diabetes Association. Direct and Indirect Costs of Diabetes in the United States in 1992. Alexandria, Va: American Diabetes Association; 1993:27.
25. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657-1664.
26. Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH. Comparative measurement sensitivity of short and longer health status instruments. Med Care. 1992;30:917-925.
27. Winward Solutions Professional DiaSym, Version 4.2. Winward Solutions Inc: Sunnyvale, Calif; 1996.
28. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. Diabetes Care. 1997;20:725-734.